At a median follow-up of 1.5 years, promising data from the 320 mg expansion cohort of phase 1/1b study shows no progression in patients with treatment-naïve CLL treated with sonrotoclax, a ...
The early research, presented at the 66th American Society of Haematology (ASH) Annual Meeting and Exposition (Abstract 4), suggests a potentially economical way to enhance CAR T cell function and ...
By exploring the conservation and functional diversity of RIPK3 and related RHIM-containing proteins across vertebrates, this important work sheds light on the e ...
Kite, a Gilead Company , today announced findings from three new analyses for Yescarta® (axicabtagene ciloleucel) that demonstrate improved outcomes for people living with relapsed or refractory (R/R) ...